$ATAI
ATAI Life Sciences N.V.

2024 Q4 Form 10-Q Financial Statement

#000095017024126515 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $40.00K
YoY Change -54.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.27M
YoY Change -24.69%
% of Gross Profit
Research & Development $12.38M
YoY Change -6.87%
% of Gross Profit
Depreciation & Amortization $83.00K
YoY Change 3.75%
% of Gross Profit
Operating Expenses $22.64M
YoY Change -15.89%
Operating Profit -$22.60M
YoY Change -15.77%
Interest Expense $147.0K
YoY Change -78.57%
% of Operating Profit
Other Income/Expense, Net -$3.861M
YoY Change -105.46%
Pretax Income -$26.46M
YoY Change -160.35%
Income Tax -$200.0K
% Of Pretax Income
Net Earnings -$26.29M
YoY Change -159.41%
Net Earnings / Revenue -65715.0%
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 167.8M 167.8M
Diluted Shares Outstanding 160.6M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.92M
YoY Change -58.89%
Cash & Equivalents $30.00M
Short-Term Investments $55.96M
Other Short-Term Assets $919.0K
YoY Change 44.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $114.1M
YoY Change -47.15%
LONG-TERM ASSETS
Property, Plant & Equipment $865.0K
YoY Change -12.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $2.428M
YoY Change -21.85%
Total Long-Term Assets $83.45M
YoY Change -9.69%
TOTAL ASSETS
Total Short-Term Assets $114.1M
Total Long-Term Assets $83.45M
Total Assets $197.5M
YoY Change -35.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.880M
YoY Change -11.37%
Accrued Expenses $11.95M
YoY Change -8.11%
Deferred Revenue
YoY Change
Short-Term Debt $56.00M
YoY Change -57.74%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $19.64M
YoY Change -0.26%
LONG-TERM LIABILITIES
Long-Term Debt $20.34M
YoY Change 32.05%
Other Long-Term Liabilities $8.378M
YoY Change 206.21%
Total Long-Term Liabilities $8.378M
YoY Change 206.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.64M
Total Long-Term Liabilities $8.378M
Total Liabilities $51.20M
YoY Change 28.95%
SHAREHOLDERS EQUITY
Retained Earnings -$661.2M
YoY Change 24.15%
Common Stock $18.77M
YoY Change 1.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $145.7M
YoY Change
Total Liabilities & Shareholders Equity $197.5M
YoY Change -35.92%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$26.29M
YoY Change -159.41%
Depreciation, Depletion And Amortization $83.00K
YoY Change 3.75%
Cash From Operating Activities -$19.34M
YoY Change 4.94%
INVESTING ACTIVITIES
Capital Expenditures $1.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $24.84M
YoY Change -153.44%
Cash From Investing Activities $24.84M
YoY Change -153.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.894M
YoY Change
NET CHANGE
Cash From Operating Activities -19.34M
Cash From Investing Activities 24.84M
Cash From Financing Activities 4.894M
Net Change In Cash 10.39M
YoY Change -116.01%
FREE CASH FLOW
Cash From Operating Activities -$19.34M
Capital Expenditures $1.000K
Free Cash Flow -$19.34M
YoY Change 4.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001840904
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset
CY2024Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40493
dei Entity Registrant Name
EntityRegistrantName
ATAI Life Sciences N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
ATAI Life Sciences N.V.
dei Entity Address Address Line2
EntityAddressAddressLine2
Wallstraße 16
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10179
dei Entity Address City Or Town
EntityAddressCityOrTown
Berlin
dei Entity Address Country
EntityAddressCountry
DE
dei City Area Code
CityAreaCode
49 89
dei Local Phone Number
LocalPhoneNumber
2153 9035
dei Security12b Title
Security12bTitle
Common shares, par value €0.10 per share
dei Trading Symbol
TradingSymbol
ATAI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
167802396
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29963000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45034000
CY2024Q3 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
55957000
CY2023Q4 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
109223000
CY2024Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
15000000
CY2023Q4 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
0
CY2024Q3 atai Committed Investment Funds
CommittedInvestmentFunds
0
CY2023Q4 atai Committed Investment Funds
CommittedInvestmentFunds
25000000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7454000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5830000
CY2024Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
5700000
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
505000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
114074000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
185592000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
865000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
981000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1032000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1223000
CY2024Q3 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
45227000
CY2023Q4 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
89825000
CY2024Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
33893000
CY2023Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
1838000
CY2024Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
0
CY2023Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
97000
CY2024Q3 us-gaap Notes Receivable By Owner To Limited Liability Company Llc
NotesReceivableByOwnerToLimitedLiabilityCompanyLLC
0
CY2023Q4 us-gaap Notes Receivable By Owner To Limited Liability Company Llc
NotesReceivableByOwnerToLimitedLiabilityCompanyLLC
11202000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2428000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2720000
CY2024Q3 us-gaap Assets
Assets
197519000
CY2023Q4 us-gaap Assets
Assets
293478000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4880000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4589000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11953000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15256000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
257000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
275000
CY2024Q3 atai Short Term Convertible Promissory Notes And Derivative Liability Related Party
ShortTermConvertiblePromissoryNotesAndDerivativeLiabilityRelatedParty
925000
CY2023Q4 atai Short Term Convertible Promissory Notes And Derivative Liability Related Party
ShortTermConvertiblePromissoryNotesAndDerivativeLiabilityRelatedParty
0
CY2024Q3 atai Short Term Convertible Promissory Notes And Derivative Liability
ShortTermConvertiblePromissoryNotesAndDerivativeLiability
1481000
CY2023Q4 atai Short Term Convertible Promissory Notes And Derivative Liability
ShortTermConvertiblePromissoryNotesAndDerivativeLiability
0
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
147000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19643000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20120000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
650000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
620000
CY2024Q3 atai Contingent Consideration Liability
ContingentConsiderationLiability
1388000
CY2023Q4 atai Contingent Consideration Liability
ContingentConsiderationLiability
1637000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
808000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
990000
CY2024Q3 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
0
CY2023Q4 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
164000
CY2024Q3 atai Convertible Promissory Notes And Derivative Liability Noncurrent
ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent
0
CY2023Q4 atai Convertible Promissory Notes And Derivative Liability Noncurrent
ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent
2666000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
20336000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
15047000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8378000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7918000
CY2024Q3 us-gaap Liabilities
Liabilities
51203000
CY2023Q4 us-gaap Liabilities
Liabilities
49162000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.11
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
167818316
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
167818316
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166026396
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166026396
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
18770000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18573000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
808355000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
794787000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20156000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19460000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-661249000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-550938000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
145720000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
242962000
CY2024Q3 us-gaap Minority Interest
MinorityInterest
596000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1354000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
146316000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
244316000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
197519000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
293478000
CY2024Q3 us-gaap Revenues
Revenues
40000
CY2023Q3 us-gaap Revenues
Revenues
87000
us-gaap Revenues
Revenues
313000
us-gaap Revenues
Revenues
296000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12377000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13290000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
36513000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
48047000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10265000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13631000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36226000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44159000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
22642000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
26921000
us-gaap Operating Expenses
OperatingExpenses
72739000
us-gaap Operating Expenses
OperatingExpenses
92206000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22602000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26834000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72426000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91910000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
160000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
612000
us-gaap Investment Income Interest
InvestmentIncomeInterest
585000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1191000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
783000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
686000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2172000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1965000
CY2024Q3 atai Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
-31000
CY2023Q3 atai Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
0
atai Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
-617000
atai Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
-0
CY2024Q3 atai Change In Fair Value Of Assets And Liabilities Net
ChangeInFairValueOfAssetsAndLiabilitiesNet
-1964000
CY2023Q3 atai Change In Fair Value Of Assets And Liabilities Net
ChangeInFairValueOfAssetsAndLiabilitiesNet
70810000
atai Change In Fair Value Of Assets And Liabilities Net
ChangeInFairValueOfAssetsAndLiabilitiesNet
-33764000
atai Change In Fair Value Of Assets And Liabilities Net
ChangeInFairValueOfAssetsAndLiabilitiesNet
72411000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
770000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
253000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
676000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-593000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2075000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-308000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2737000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3861000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
70681000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-36795000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
70944000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-26463000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
43847000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-109221000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20966000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-178000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
238000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-163000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
588000
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-26000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-238000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3199000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-26311000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
us-gaap Profit Loss
ProfitLoss
-111058000
us-gaap Profit Loss
ProfitLoss
-24753000
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-25000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-873000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-747000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2821000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-26286000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
44244000
us-gaap Net Income Loss
NetIncomeLoss
-110311000
us-gaap Net Income Loss
NetIncomeLoss
-21932000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160621817
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155792490
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159973201
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155793601
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160621817
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177565973
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159973201
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155793601
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-26311000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
us-gaap Profit Loss
ProfitLoss
-111058000
us-gaap Profit Loss
ProfitLoss
-24753000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-985000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1709000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-696000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2593000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-27296000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
45080000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-111754000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-22160000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
25000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
873000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
747000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2821000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-22000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
22000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-11000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
31000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-47000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-851000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-758000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2790000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27249000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
45931000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110996000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19370000
CY2023Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
244316000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5760000
CY2024Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
559000
CY2024Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-27378000
CY2024Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
223257000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
326000
CY2024Q2 atai Adjustment To Additional Paid In Capital Upon Consolidation Of Variable Interest Entity Net
AdjustmentToAdditionalPaidInCapitalUponConsolidationOfVariableInterestEntityNet
-115000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6282000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-3590000
CY2024Q2 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-259000
CY2024Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-57369000
CY2024Q2 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
168533000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5046000
CY2024Q3 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-1007000
CY2024Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-26311000
CY2024Q3 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
146316000
CY2022Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
265766000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
181000
CY2023Q1 atai Settlement Of Issuance Of Common Shares Value
SettlementOfIssuanceOfCommonSharesValue
24000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8662000
CY2023Q1 atai Adjustment To Accumulated Deficit Pursuant To Adoption Of Asu201613
AdjustmentToAccumulatedDeficitPursuantToAdoptionOfAsu201613
-526000
CY2023Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
887000
CY2023Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-34354000
CY2023Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
240640000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8762000
CY2023Q2 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
6000
CY2023Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-33771000
CY2023Q2 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
215637000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8253000
CY2023Q3 atai Adjustment To Additional Paid In Capital Upon Consolidation Of Variable Interest Entity Net
AdjustmentToAdditionalPaidInCapitalUponConsolidationOfVariableInterestEntityNet
-480000
CY2023Q3 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
1731000
CY2023Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
43371000
CY2023Q3 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
268512000
us-gaap Profit Loss
ProfitLoss
-111058000
us-gaap Profit Loss
ProfitLoss
-24753000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
248000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
218000
atai Noncash Lease Expense
NoncashLeaseExpense
202000
atai Noncash Lease Expense
NoncashLeaseExpense
297000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
327000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
272000
us-gaap Share Based Compensation
ShareBasedCompensation
17088000
us-gaap Share Based Compensation
ShareBasedCompensation
25677000
atai Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
-35965000
atai Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
72411000
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
2075000
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
0
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
789000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-555000
atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
2000000
atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
3199000
atai Other Income And Expense
OtherIncomeAndExpense
-965000
atai Other Income And Expense
OtherIncomeAndExpense
42000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1599000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6716000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
261000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3096000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3827000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4980000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58142000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62156000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
54270000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
130363000
atai Proceeds From Sale Of Other Investment Held At Fair Value
ProceedsFromSaleOfOtherInvestmentHeldAtFairValue
16093000
atai Proceeds From Sale Of Other Investment Held At Fair Value
ProceedsFromSaleOfOtherInvestmentHeldAtFairValue
0
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
177047000
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
10000000
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0
atai Cash Paid For Short Term Convertible Notes Receivable And Warrant Related Party
CashPaidForShortTermConvertibleNotesReceivableAndWarrantRelatedParty
2000000
atai Cash Paid For Short Term Convertible Notes Receivable And Warrant Related Party
CashPaidForShortTermConvertibleNotesReceivableAndWarrantRelatedParty
0
atai Cash Paid For Short Term Notes Receivable Related Party
CashPaidForShortTermNotesReceivableRelatedParty
5745000
atai Cash Paid For Short Term Notes Receivable Related Party
CashPaidForShortTermNotesReceivableRelatedParty
0
us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
0
us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
atai Cash Paid For Convertible Notes Receivable Related Party
CashPaidForConvertibleNotesReceivableRelatedParty
0
atai Cash Paid For Convertible Notes Receivable Related Party
CashPaidForConvertibleNotesReceivableRelatedParty
1497000
atai Cash Paid For Other Investments Held At Fair Value
CashPaidForOtherInvestmentsHeldAtFairValue
0
atai Cash Paid For Other Investments Held At Fair Value
CashPaidForOtherInvestmentsHeldAtFairValue
724000
us-gaap Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
0
us-gaap Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
480000
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
486000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
6000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
322000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
251000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
52612000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52472000
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
5000000
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
381000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
206000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
161000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
100000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5220000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
239000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
401000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-71000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-114121000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45034000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190613000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44963000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76492000
us-gaap Income Taxes Paid
IncomeTaxesPaid
376000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1475000
us-gaap Interest Paid Net
InterestPaidNet
1654000
us-gaap Interest Paid Net
InterestPaidNet
1428000
atai Noncash Exchange Of Convertible Promissory Note Modification
NoncashExchangeOfConvertiblePromissoryNoteModification
3586000
atai Noncash Exchange Of Convertible Promissory Note Modification
NoncashExchangeOfConvertiblePromissoryNoteModification
0
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
0
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
atai Noncash Commitment For Debtor In Possession Loan
NoncashCommitmentForDebtorInPossessionLoan
147000
atai Noncash Commitment For Debtor In Possession Loan
NoncashCommitmentForDebtorInPossessionLoan
0
atai Noncash Consideration For Variable Interest Deconsolidation
NoncashConsiderationForVariableInterestDeconsolidation
115000
atai Noncash Consideration For Variable Interest Deconsolidation
NoncashConsiderationForVariableInterestDeconsolidation
0
us-gaap Nature Of Operations
NatureOfOperations
<p id="footnotes" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Or</span><span id="notes"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ganization and Description of Business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATAI Life Sciences N.V. (“atai" or the "Company"), headquartered in Berlin, Germany is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape and is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, third-party clinical research organizations and manufacturers, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates and manages the business as one reportable segment, which is the business of identifying and advancing mental health innovations. The Company has determined that its chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews consolidated operating expenses to make decisions about allocating resources or capital to specific compounds or projects in line with overall Company’s strategies and goals. The Company operates in two geographic regions primarily in the United States and Germany.</span></p><p style="margin-left:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and short-term securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">56.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">661.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company has historically financed its operations through the sale of equity securities, debt financings, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of September 30, 2024 will be </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the unaudited condensed consolidated financial statements are issued.</span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30000000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
15000000
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
56000000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-661200000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1354000
CY2024Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-665000
CY2024Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
24000
CY2024Q1 us-gaap Minority Interest
MinorityInterest
713000
CY2024Q2 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-57000
CY2024Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-13000
CY2024Q2 us-gaap Minority Interest
MinorityInterest
643000
CY2024Q3 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-25000
CY2024Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-22000
CY2024Q3 us-gaap Minority Interest
MinorityInterest
596000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
5026000
CY2023Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-1219000
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
8000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
3815000
CY2023Q2 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-729000
CY2023Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
1000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
3087000
CY2023Q3 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-873000
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
22000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
2236000
CY2024Q3 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
15000000
CY2023Q4 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
6100000
CY2023Q4 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
100000
CY2024Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
2100000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q4 atai Deferred Purchase Credit
DeferredPurchaseCredit
5100000
CY2024Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
33893000
CY2023Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
1838000
atai Equity Method Investment Shares Transaction Date
EquityMethodInvestmentSharesTransactionDate
2026-12-31
us-gaap Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions
9600000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2400000
CY2023 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2400000
CY2024Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
900000
CY2023Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
1800000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
3200000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
3300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.786
CY2024Q3 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
4208000
CY2023Q4 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
1822000
CY2024Q3 us-gaap Prepaid Taxes
PrepaidTaxes
1253000
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
1752000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1074000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1410000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
919000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
846000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7454000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5830000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4540000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5468000
CY2024Q3 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3657000
CY2023Q4 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3031000
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2350000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4941000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1114000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1101000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
182000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
715000
CY2024Q3 atai Accrued Restructuring Costs
AccruedRestructuringCosts
110000
CY2023Q4 atai Accrued Restructuring Costs
AccruedRestructuringCosts
0
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11953000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15256000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1032000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1223000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
257000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
808000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
990000
CY2024Q3 atai Operating Leases Future Minimum Payment Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentReceivableRemainderOfFiscalYear
94000
CY2024Q3 atai Operating Leases Future Minimum Payment Receivable In Two Years
OperatingLeasesFutureMinimumPaymentReceivableInTwoYears
375000
CY2024Q3 atai Operating Leases Future Minimum Payment Receivable Inthree Years
OperatingLeasesFutureMinimumPaymentReceivableInthreeYears
375000
CY2024Q3 atai Operating Leases Future Minimum Payment Receivable In Four Years
OperatingLeasesFutureMinimumPaymentReceivableInFourYears
375000
CY2024Q3 atai Operating Leases Future Minimum Payment Receivable In Five Years
OperatingLeasesFutureMinimumPaymentReceivableInFiveYears
125000
CY2024Q3 atai Operating Leases Future Minimum Payment Receivable
OperatingLeasesFutureMinimumPaymentReceivable
1344000
CY2024Q3 us-gaap Receivable With Imputed Interest Discount
ReceivableWithImputedInterestDiscount
279000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1065000
atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
326000
atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
304000
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
0
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
CY2023Q4 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
16
CY2024Q2 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
16
CY2024Q3 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
1000000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
3900000
CY2022Q3 us-gaap Principal Amount Outstanding Of Loans Held In Portfolio
PrincipalAmountOutstandingOfLoansHeldInPortfolio
175000000
CY2024Q3 atai Borrowing Amount Percentage
BorrowingAmountPercentage
0.70
CY2024Q3 atai Accrued Interest Payable
AccruedInterestPayable
0.0905
CY2024Q3 atai Prime Rate Percent
PrimeRatePercent
0.043
CY2024Q3 us-gaap Loans Held For Sale Maturity Date
LoansHeldForSaleMaturityDate
2026-08-01
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
175000000
CY2024Q3 atai Prime Rate Percent
PrimeRatePercent
0.043
CY2024Q3 atai Accrued Interest Payable
AccruedInterestPayable
0.0905
CY2022Q3 atai Borrowing Amount Percentage
BorrowingAmountPercentage
0.70
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2024Q3 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2023Q4 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-144000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-204000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-60000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-84000
CY2024Q3 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-502000
CY2023Q4 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-707000
CY2024Q3 atai Certain Loans Acquired In Transfer Accounted For Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForDebtSecuritiesCarryingAmountNet
20336000
CY2023Q4 atai Certain Loans Acquired In Transfer Accounted For Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForDebtSecuritiesCarryingAmountNet
15047000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
20336000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
15047000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.97
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-26311000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
us-gaap Profit Loss
ProfitLoss
-111058000
us-gaap Profit Loss
ProfitLoss
-24753000
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-25000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-873000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-747000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2821000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26286000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
44244000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110311000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21932000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-26311000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
us-gaap Profit Loss
ProfitLoss
-111058000
us-gaap Profit Loss
ProfitLoss
-24753000
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-25000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-873000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-747000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2821000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26286000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
44244000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-110311000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21932000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160621817
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177565973
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159973201
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155793601
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
56172183
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34896194
CY2024Q3 atai Revenue Related To Certain Research And Development
RevenueRelatedToCertainResearchAndDevelopment
100000
CY2023Q3 atai Revenue Related To Certain Research And Development
RevenueRelatedToCertainResearchAndDevelopment
100000
atai Revenue Related To Certain Research And Development
RevenueRelatedToCertainResearchAndDevelopment
300000
atai Revenue Related To Certain Research And Development
RevenueRelatedToCertainResearchAndDevelopment
300000
atai Related Party Reservation Rate Of Common Shares For Ipo
RelatedPartyReservationRateOfCommonSharesForIpo
0.27
CY2024Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
100000
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
100000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
300000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
400000
CY2024Q1 atai Percentage Of Restructed Workforce
PercentageOfRestructedWorkforce
0.10
us-gaap Restructuring Costs
RestructuringCosts
2000000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
100000
CY2023Q1 atai Percentage Of Restructed Workforce
PercentageOfRestructedWorkforce
0.30
us-gaap Restructuring Costs
RestructuringCosts
3200000
us-gaap Restructuring Costs
RestructuringCosts
2026000
us-gaap Restructuring Costs
RestructuringCosts
3206000
atai Non Cash Impact Of Stock Based Compensation
NonCashImpactOfStockBasedCompensation
358000
atai Non Cash Impact Of Stock Based Compensation
NonCashImpactOfStockBasedCompensation
195000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1558000
us-gaap Payments For Restructuring
PaymentsForRestructuring
3011000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
110000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-126515-index-headers.html Edgar Link pending
0000950170-24-126515-index.html Edgar Link pending
0000950170-24-126515.txt Edgar Link pending
0000950170-24-126515-xbrl.zip Edgar Link pending
atai-20240930.htm Edgar Link pending
atai-20240930.xsd Edgar Link pending
atai-ex31_1.htm Edgar Link pending
atai-ex31_2.htm Edgar Link pending
atai-ex31_3.htm Edgar Link pending
atai-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img106867992_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
atai-20240930_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable